These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 8157459)

  • 21. Vaccine procurement and self-sufficiency in developing countries.
    Woodle D
    Health Policy Plan; 2000 Jun; 15(2):121-9. PubMed ID: 10837034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunization in developing countries: practical and theoretical problems and prospects.
    Arya SC
    Vaccine; 1994 Nov; 12(15):1423-35. PubMed ID: 7887021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UNICEF redefines roles, but remains "firmly committed" to immunization.
    CVI Forum; 1992 Oct; (2):2-3. PubMed ID: 12321773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An economic evaluation of "Health for All".
    Patel M
    Health Policy Plan; 1986 Mar; 1(1):37-47. PubMed ID: 10312155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Towards a new vaccine economy?].
    Poirot P; Martin JF
    Sante; 1994; 4(3):183-7. PubMed ID: 7921683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vaccines: producers in countries of the Southern hemisphere].
    Bertrand JJ
    Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Children's vaccine initiative.
    World Health Forum; 1993; 14(2):202-3. PubMed ID: 8185773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global support for new vaccine implementation in middle-income countries.
    Kaddar M; Schmitt S; Makinen M; Milstien J
    Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Availability of quality vaccines: policies of a non-government organization.
    Poore P
    Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The imperative for stronger vaccine supply and logistics systems.
    Zaffran M; Vandelaer J; Kristensen D; Melgaard B; Yadav P; Antwi-Agyei KO; Lasher H
    Vaccine; 2013 Apr; 31 Suppl 2():B73-80. PubMed ID: 23598495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Geneva-Seattle collaboration in support of developing country vaccine manufacturing.
    Stevenson MA
    Glob Public Health; 2018 Apr; 13(4):426-441. PubMed ID: 27760489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transferring manufacturing technology. Producing essential vaccines in Pakistan.
    Burney MI
    Int J Technol Assess Health Care; 1993; 9(3):397-406. PubMed ID: 8340204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting scientific advances. Philip Russell.
    CVI Forum; 1992 Apr; (1):3-5. PubMed ID: 12321835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines, inspiring innovation in health.
    Pagliusi S; Dennehy M; Kim H;
    Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives.
    Cortes Mde L; Cardoso D; Fitzgerald J; DiFabio JL
    Biologicals; 2012 Jan; 40(1):3-14. PubMed ID: 22033155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustainable vaccine manufacturing in low- and middle-Income countries.
    Hayman B; Kumar Suri R; Downham M
    Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.